Tag: fund

ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the fiscal first quarter of 2025 which ended April 30, 2025.

TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- Middlefield Group (“Middlefield”) announced today that it has concluded the risk rating review of its Mutual Funds. The risk rating of Middlefield Innovation Dividend Class has been increased from Medium to Medium-to-High, and the risk rating of Middlefield Global Infrastructure Fund has been increased from Low-Medium to Medium. These changes are reflected in the Prospectus and the respective Fund Facts dated June 16, 2025. The risk rating change is effective immediately and is based on the risk classification methodology mandated by the Canadian Securities Administrators, in accordance with National Instrument 81-102 Investment Funds.

The net asset value (NAV) per unit of the Baltic Horizon Fund (the Fund) increased to EUR 0.6757 at the end of May 2025 (0.6740 as of 30 April 2025). The month-end total net asset value of the Fund was EUR 97.0 million (EUR 96.8 million as of 30 April 2025). The EPRA NRV as of 31 May 2025 stood at EUR 0.7216 per unit.

Chicago, Illinois, June 16, 2025 (GLOBE NEWSWIRE) -- Mag Mile Capital, Inc. (OTCQB: MMCP) ("Mag Mile", or the "Company") is pleased to announce the successful arrangement of $10.25 million in joint venture equity on behalf of the development team executing an innovative Class A office-to-multifamily conversion project at 111 W. Illinois in the River North neighborhood of Chicago, IL.

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- Espada Energy Partners, LLC (“Espada”) today announced the closing of an equity commitment from an investment fund managed by Carnelian Energy Capital Management, L.P. (“Carnelian”).  

Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today announced an extension of their collaboration for medical radioisotope production, originally established in 2009. Under the terms of the renewed agreement, ITM will receive priority access to half of the available neutron irradiation capacity at ILL’s High-Flux Reactor, its neutron irradiation facility, for the production of non-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used for radiopharmaceutical therapies for cancer treatment and diagnosis. As the globally leading manufacturer of n.c.a. Lu-177, ITM is committed to maintaining and expanding its robust manufacturing and production capabilities to meet the growing demand for this vital medical radioisotope.